Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04229862
Other study ID # 2020-0020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 14, 2020
Est. completion date May 5, 2020

Study information

Verified date May 2020
Source Asan Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the first attempt success rate of laryngeal mask airway insertion according to the degree of head elevation.


Description:

The purpose of this study is to compare the first attempt success rate of laryngeal mask airway insertion between 7 cm head elevation and 14 cm head elevation in patients who undergoing transurethral bladder tumor resection.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date May 5, 2020
Est. primary completion date April 5, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 79 Years
Eligibility Inclusion Criteria:

- Patients who are scheduled transurethral bladder tumor resection under general anesthesia

- 20-79 years of age

- American Society of Anesthesiologists physical status =3

- Patients who are voluntarily agreed to this clinical study

Exclusion Criteria:

- History of difficult airway

- Expected difficult airway by physical examination

- Unstable teeth or teeth loss

- Obesity (body mass index = 30)

- Recent history of upper respiratory infection

- Patients who are not fasted or who are at risk of aspiration

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Laryngeal mask airway insertion
Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (5)

Horton WA, Fahy L, Charters P. Defining a standard intubating position using "angle finder". Br J Anaesth. 1989 Jan;62(1):6-12. — View Citation

Jun JH, Baik HJ, Kim JH, Kim YJ, Chang RN. Comparison of the ease of laryngeal mask airway ProSeal insertion and the fiberoptic scoring according to the head position and the presence of a difficult airway. Korean J Anesthesiol. 2011 Apr;60(4):244-9. doi: 10.4097/kjae.2011.60.4.244. Epub 2011 Apr 26. — View Citation

Katsiampoura AD, Killoran PV, Corso RM, Cai C, Hagberg CA, Cattano D. Laryngeal mask placement in a teaching institution: analysis of difficult placements. F1000Res. 2015 Apr 29;4:102. doi: 10.12688/f1000research.6415.1. eCollection 2015. — View Citation

Mohta M. Head elevation beyond sniffing position - An aid to airway management. J Anaesthesiol Clin Pharmacol. 2018 Apr-Jun;34(2):247-248. doi: 10.4103/joacp.JOACP_173_17. — View Citation

Takenaka I, Aoyama K, Iwagaki T, Ishimura H, Kadoya T. The sniffing position provides greater occipito-atlanto-axial angulation than simple head extension: a radiological study. Can J Anaesth. 2007 Feb;54(2):129-33. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary First attempt success rate The rate of success at the first attempt of laryngeal mask airway insertion Immediately after mask airway insertion
Secondary The percentage of glottic opening score The percentage of glottic opening by fiberoptic view Immediately after mask airway insertion
Secondary Laryngeal mask airway insertion-related patient satisfaction A seven-point Likert scale At postoperative 6 hours
Secondary Second attempt success rate The rate of success at the second attempt of laryngeal mask airway insertion Immediately after mask airway insertion
Secondary Third attempt success rate The rate of success at the third attempt of laryngeal mask airway insertion Immediately after mask airway insertion
Secondary Oropharyngeal leak pressure Oropharyngeal leak pressure is measured as follows: After setting the expiratory valve to 30 cmH2O at a fixed gas flow rate of 3 L/min, the maximum inflation pressure is measured when a noise of gas leakage is heard in the oropharynx via a stethoscope. Immediately after mask airway insertion
Secondary Reposition rate The rate of reposition after laryngeal mask airway insertion when ventilation is ineffective or air leaks After mask airway insertion (up to end of surgery)
Secondary Complications associated with laryngeal mask airway insertion Complications related with laryngeal mask airway insertion such as cough, vomit, aspiration, regurgitation, bleeding, laryngospasm, and bronchospasm Up to postoperative 3 days
See also
  Status Clinical Trial Phase
Terminated NCT02612194 - LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT02805608 - uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer Phase 2
Not yet recruiting NCT02534623 - Postoperative Quality of Recovery After Transurethral Resection of the Bladder N/A
Recruiting NCT02228473 - Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Terminated NCT02560038 - Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer Phase 2
Not yet recruiting NCT02252445 - Propofol and Sevoflurane for Catheter-Related Bladder Discomfort N/A
Not yet recruiting NCT02760953 - TURBt With Adjuvant Cryoablation to Treat Bladder Cancer N/A
Terminated NCT04430036 - AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Phase 2
Active, not recruiting NCT06289283 - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03404791 - A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy Phase 1
Terminated NCT01479348 - Imaging Study for FdCyd and THU Cancer Treatment Early Phase 1
Recruiting NCT05742867 - A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder